Literature DB >> 3002039

A common mouse mammary tumor virus integration site in chemically induced precancerous mammary hyperplasias.

D A Gray, C M McGrath, R F Jones, V L Morris.   

Abstract

Mammary carcinomas can be induced by chemical and hormonal as well as viral carcinogens. Irrespective of the class of inducer, these tumors develop in discrete stages, of which alveolar hyperplasia is one of the earliest identifiable. Since carcinogenesis by the mammary tumor virus is now thought to involve proviral activation of adjacent cell genes at specific loci, we sought to determine if a similar mechanism also played a role in chemical and hormonal carcinogenesis and if its role was stage specific. Three high-tumor-incidence BALB/c hyperplastic alveolar nodule outgrowths of two different etiologies were found to have exogenous mouse mammary tumor virus proviruses integrated at the same site in the genome. This common site of integration is not within the bounds of the int-1 and int-2 loci into which proviruses detected at these loci are clustered in MMTV-induced mammary tumors. All three HANs are commonly impaired in end-point differentiation. We propose that mouse mammary tumor virus integration at this site is responsible for a specific abnormality in differentiation associated with the preneoplastic phenotype.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3002039     DOI: 10.1016/0042-6822(86)90332-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion.

Authors:  Gouri Chatterjee; Andrea Rosner; Yi Han; Edward T Zelazny; Baolin Li; Robert D Cardiff; Archibald S Perkins
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer.

Authors:  Philip H Jones; Wadie D Mahauad-Fernandez; Marisa N Madison; Chioma M Okeoma
Journal:  Virology       Date:  2013-06-25       Impact factor: 3.616

3.  Nonrandom distribution of MMTV proviral sequences in the mouse genome.

Authors:  J Salinas; M Zerial; J Filipski; M Crepin; G Bernardi
Journal:  Nucleic Acids Res       Date:  1987-04-10       Impact factor: 16.971

4.  Dsi-1, a region with frequent proviral insertions in Moloney murine leukemia virus-induced rat thymomas.

Authors:  S Vijaya; D L Steffen; C Kozak; H L Robinson
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

5.  Mouse mammary tumor virus carrying a bacterial supF gene has wild-type pathogenicity and enables rapid isolation of proviral integration sites.

Authors:  Z Jiang; G M Shackleford
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  A putative int domain for mouse mammary tumor virus on mouse chromosome 7 is a 5' extension of int-2.

Authors:  G Peters; S Brookes; M Placzek; M Schuermann; R Michalides; C Dickson
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

7.  Expression of the int-1 and int-2 loci in endogenous mouse mammary tumor virus-induced mammary tumorigenesis in the C3Hf mouse.

Authors:  P R Etkind
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

Review 8.  The preneoplastic phenotype in murine mammary tumorigenesis.

Authors:  D Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

9.  Mouse mammary tumor virus integration site selection in human and mouse genomes.

Authors:  Alexander Faschinger; Francoise Rouault; Johannes Sollner; Arno Lukas; Brian Salmons; Walter H Günzburg; Stanislav Indik
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

10.  fim-1 and fim-2: two new integration regions of Friend murine leukemia virus in myeloblastic leukemias.

Authors:  B Sola; S Fichelson; D Bordereaux; P E Tambourin; S Gisselbrecht
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.